| Overview |
| bs-8158R |
| HCV NS5A transactivated protein 8 Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human BTBD1/HCV NS5A transactivated protein 8 |
| 401-482/482 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 53339 |
| Cytoplasm |
| BTB POZ domain containing 1; BTB domain containing 1; BTB/POZ domain containing protein 1; BTBD 1; C15orf1; HCV NS5A transactivated protein 8; Hepatitis C virus NS5A transactivated protein 8; NS5ATP8; BTBD1_HUMAN. |
| BTBD1 contains a proline-rich region and a BTB/POZ domain which are typically involved in protein-protein interactions. The C-terminus of BTBD1 binds topoisomerase I and BTBD1 also interacts with TRIM5 isoform Delta. BTBD1 localizes to cytoplasmic bodies and is essential for myogenic differentiation. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz